Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881830 | 0.96 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL243579 | 0.96 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL243788 | 0.94 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL241232 | 0.88 | AGTR1 (0.88) | AGTR1AGTR2 | |
| SCHEMBL242222 | 0.87 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL7406561 | 0.85 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL243199 | 0.85 | AGTR1 (1.00) | AGTR1AGTR2 | |
| SCHEMBL2882133 | 0.83 | AGTR1 (0.78) | AGTR1AGTR2 | |
| SCHEMBL245015 | 0.83 | AGTR1 (0.94) | AGTR1AGTR2 | |
| SCHEMBL7932871 | 0.83 | AGTR1 (1.00) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9227968-B2 | Method of treatment or prophylaxis of inflammatory pain | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9018207-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-28 | — | — | US | disclosed |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-08-14 | — | — | US | disclosed |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| US-8722675-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-13 | — | — | US | disclosed |
| US-20130296350-A1 | Method of Treatment or Prophylaxis | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | disclosed |
| US-8492382-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| US-8404686-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-03-26 | — | — | US | disclosed |
| US-20120004259-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | SPINIFEX PHARMACEUTICALS, PTY LTD (AU) | 2012-01-05 | — | — | US | disclosed |
| US-20110318329-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | UNIVERSITY OF QUEENSLAND (AU) | 2010-11-18 | — | — | US | disclosed |
| US-7828840-B2 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | MED INSTITUTE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7795275-B2 | Method of treatment or prophylaxis | UNIQUEST PTY LIMITED (AU) | 2010-09-14 | — | — | US | disclosed |
| US-20090177267-A1 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2009-07-09 | — | — | US | disclosed |
| US-20060223741-A1 | Method of treatment or prophylaxis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-10-05 | — | — | US | disclosed |
| US-5545651-A | HYPOTENSIVE AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| US-5395844-A | Hypotensive agents; congestive heart failure | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296350-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20060223741-A1 | Method of treatment or prophylaxis | AGTR2, AGTR1, NTSR2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20120004259-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | AGTR2, AGTR1, NTSR2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20110318329-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | AGTR2, AGTR1, NTSR2 | AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.